3-6-dihydroxyflavone has been researched along with Prostatic-Neoplasms* in 1 studies
1 other study(ies) available for 3-6-dihydroxyflavone and Prostatic-Neoplasms
| Article | Year |
|---|---|
Cytotoxic flavonoids as agonists of peroxisome proliferator-activated receptor gamma on human cervical and prostate cancer cells.
We conducted in silico screening for human peroxisome proliferator-activated receptor gamma (hPPARgamma) by performing an automated docking study with 450 flavonoids. Among the eight flavonoids as possible agonists of hPPARgamma, only 3,6-dihydroxyflavone (4) increased the binding between PPARgamma and steroid receptor coactivator-1 (SRC-1), approximately 5-fold, and showed one order higher binding affinity for PPARgamma than a reference compound, indomethacin. The 6-hydroxy group of the A-ring of 3,6-dihydroxyflavone (4) participated in hydrogen-bonding interactions with the side chain of Tyr327, His449, and Tyr473. The B-ring formed a hydrophobic interaction with Leu330, Leu333, Val339, Ile341, and Met364. Therefore, 3,6-dihydroxyflavone is a potent agonist of hPPAR with cytotoxic effects on human cervical and prostate cancer cells. Topics: Antineoplastic Agents; Drug Screening Assays, Antitumor; Female; Flavonoids; HeLa Cells; Humans; Male; Models, Molecular; PPAR gamma; Prostatic Neoplasms; Uterine Cervical Neoplasms | 2010 |